GHK vs GHK-Cu: What's the Difference in the Research?

Few questions come up more often in the peptide research category than this one: are GHK and GHK-Cu the same thing, and if not, which one does the published literature actually describe? The two names are used interchangeably in marketing copy, in supplier listings, and even in some review articles. They are not the same compound, and for laboratory design purposes the difference is not trivial.

GHK is the tripeptide glycyl-L-histidyl-L-lysine. GHK-Cu is the copper(II) complex of that tripeptide. One is the parent peptide; the other is the peptide pre-loaded with its physiologically relevant transition-metal cofactor. The two compounds share most of the published mechanism literature, but they are distinct chemical entities with different molecular weights, different colors, different stability profiles, and different roles in experimental design.

This article walks through the chemistry, the mechanism research, the animal-study and in vitro literature, and the practical considerations that determine which form a researcher should specify for a given protocol.

Quick reference: GHK vs GHK-Cu

The color difference is the fastest visual cue. GHK powder is white to off-white. GHK-Cu powder is a distinct blue, the result of the d-d electronic transitions of the coordinated copper(II) center. A “GHK-Cu” product that is pale, gray, or white is undercomplexed or mislabeled.

Chemistry — the actual difference

GHK was first isolated from human plasma by Loren Pickart in 1973, where it was identified as a tripeptide fraction that altered the behavior of cultured hepatic cells [Pickart 2008]. The molecule is small (three amino acid residues), water-soluble, and stable as a lyophilized solid at standard storage conditions.

The chemistry that makes GHK biologically interesting is its affinity for copper(II). The molecule presents three nitrogen donors that geometrically organize around a transition-metal center: the N-terminal amine of the glycine residue, the deprotonated peptide nitrogen of the Gly-His bond, and the imidazole nitrogen of the histidine side chain. Together these donors form a stable square-planar coordination geometry around Cu(II), with the lysine side chain extending away from the metal-binding site. The result is a 1:1 GHK:Cu(II) complex with a high apparent binding constant at physiological pH [Pickart and Margolina 2018].

This affinity matters in two directions. First, when GHK is dissolved in any aqueous system that contains available Cu(II) — for example, cell culture medium with trace copper, or a tissue compartment — it will spontaneously complex copper. Second, the pre-formed GHK-Cu complex is what the majority of the regenerative and tissue-remodeling literature has actually studied. When a paper from the Pickart group describes “GHK,” it almost always refers to the copper-bound form unless explicitly stated otherwise.

GHK-Cu is therefore not a separate molecule with a separate mechanism. It is GHK in the state it most often adopts under physiological conditions. The distinction between the two compounds in a research catalog is the distinction between buying the apoprotein and buying the holoprotein: same peptide backbone, different metal occupancy at the time of receipt.

Key references: [Pickart 2008]; [Pickart and Margolina 2018]; [Pickart et al. 2015].

Research mechanism — what differs at the molecular level

The published mechanism literature distinguishes the two forms in a few specific contexts.

GHK alone has been studied as a copper carrier and as a gene-expression modulator. The most-cited transcriptomic work in this area is the Broad Institute Connectivity Map analysis by Campbell and colleagues, which identified GHK as a compound capable of partially reversing a gene-expression signature associated with emphysematous lung tissue destruction in animal studies and in human bronchial epithelial cell culture [Campbell et al. 2012]. The follow-on transcriptomic work by Hong and colleagues, using cultured fibroblasts, reported that GHK-Cu treatment altered the expression of several thousand genes at a meaningful fold-change threshold [Hong et al. 2015]. These transcriptomic effects are reported for both forms in the literature, but the mechanistic interpretation often invokes copper delivery as the proximal cause downstream of binding.

GHK-Cu has been studied more extensively in tissue-repair contexts. The copper that the complex delivers is functionally important for many of the downstream pathways reported in the literature: lysyl oxidase activity, antioxidant enzyme expression, and collagen and glycosaminoglycan synthesis in fibroblast culture have all been described in studies that used the pre-formed copper complex [Maquart et al. 1988; Pickart and Margolina 2018].

The literature largely studies GHK-Cu rather than GHK-only, but some studies have compared the two directly and have reported that copper availability — whether supplied pre-complexed or co-administered — is required for the full magnitude of certain reported effects. This is the central point for experimental design: in any protocol that depends on copper-mediated downstream chemistry, GHK and GHK-Cu are not interchangeable without controlling for the copper variable.

Animal-study and in vitro literature

A non-exhaustive map of where each form appears in the published research record:

Skin tissue repair, animal studies. GHK-Cu has been studied in animal-study models of dermal wound healing, with reported effects on collagen organization and on the rate of tissue closure [Pickart and Margolina 2018, and references therein].
Lung tissue repair, animal studies. GHK-Cu has been investigated in animal-study models of pulmonary tissue injury and fibrosis, including the work by Zhou and colleagues on GHK-Cu and lung tissue repair [Zhou et al. 2012].
COPD-related transcriptomics. GHK (the free tripeptide) was the form identified by the Campbell group in the Connectivity Map analysis that flagged it as a candidate for reversing an emphysema-associated gene-expression signature [Campbell et al. 2012].
Fibroblast collagen synthesis assays, in vitro. GHK-Cu is the form historically used in the Maquart and Borel work on collagen synthesis in cultured fibroblasts [Maquart et al. 1988].
Transcriptomic profiling, in vitro. The Hong and colleagues fibroblast transcriptomic study used GHK-Cu and reported widespread changes in gene expression across pathways linked to extracellular matrix remodeling and DNA repair [Hong et al. 2015].

When designing a literature-matched protocol, the choice between GHK and GHK-Cu should follow the form used in the reference paper. A study replicating Campbell 2012 should specify GHK. A study replicating Maquart 1988 or Hong 2015 should specify GHK-Cu.

Research design considerations — when to choose which

The two compounds support different experimental designs.

Choose GHK when the protocol studies copper-delivery dependency and the researcher wants to add Cu(II) separately, at a controlled stoichiometry, as part of the experimental variable set.
Choose GHK when a non-pigmented control compound is required — for example, in a colorimetric assay where the blue Cu absorbance of GHK-Cu would confound the readout.
Choose GHK when matching the Campbell 2012 transcriptomic work and other studies that explicitly used the free tripeptide.
Choose GHK-Cu when the protocol studies the pre-complexed copper-peptide and the researcher wants a defined 1:1 starting stoichiometry without an in-situ complexation step.
Choose GHK-Cu when matching the majority of the historical regenerative and tissue-remodeling literature, including the Pickart group’s work and the Maquart/Borel collagen synthesis assays.
Choose GHK-Cu when copper availability in the experimental system (cell culture medium, buffer) is low or variable and pre-loading the peptide is the cleaner control.

The two are not interchangeable in research designs that depend on copper availability. A protocol that calls for GHK-Cu cannot be silently substituted with GHK without confirming that the system supplies sufficient bioavailable copper to drive complexation in situ.

A related consideration: stock solution pH. GHK-Cu in unbuffered water at high concentrations can show color changes and aggregation over time as the complex equilibrates. Some method papers recommend a buffered system, or freshly reconstituted aliquots, when the experimental readout is sensitive to copper redox state.

CoA and quality considerations for both

A defensible Certificate of Analysis for either compound should include identity, purity, and form-specific quantification. The expectations differ between the two.

GHK (free tripeptide) CoA expectations:

HPLC purity at or above 99.0 percent (area-percent at the specified detection wavelength)
Mass spectrometry confirming [M+H]+ at approximately 341 Da
Counterion identification (typically acetate or trifluoroacetate from synthesis workup)
Water content by Karl Fischer or by loss-on-drying
Residual solvents within ICH Q3C limits
Bacterial endotoxin (when relevant to the intended research application)
Copper content reported as below the quantitation limit, or specified as undetectable, to confirm the absence of unintended complexation during synthesis or storage

GHK-Cu (copper complex) CoA expectations:

HPLC purity at or above 99.0 percent for the peptide component
Mass spectrometry confirming the copper-complex characteristic ions and isotope pattern (Cu has a distinctive 63Cu/65Cu isotope envelope that is diagnostic on MS)
Copper content quantification, typically 13 to 16 percent by mass for the standard 1:1 mono-copper complex (the exact value depends on hydration state and counterion)
Water content by Karl Fischer
Residual solvents within ICH Q3C limits
Visual specification: blue lyophilized powder

The blue color of GHK-Cu lyophilized powder is itself a fast visual quality cue. A pale, white, or only faintly blue “GHK-Cu” product is undercomplexed and should not be accepted as the copper-loaded form without a copper-content number on the CoA to support the label.

For a fuller walkthrough of how to read these documents, see our guide on how to read a peptide CoA. Every lot ships can be cross-checked at /verify/.

Storage and handling

Both compounds are supplied as lyophilized powders and store comparably as solids at standard low-temperature, light-protected conditions. The differences appear in solution.

GHK-Cu is more sensitive to light and heat than GHK in solution because copper(II) can participate in redox chemistry that the free peptide cannot. Reconstituted GHK-Cu should be protected from prolonged light exposure and from elevated temperatures.
Reconstituted GHK-Cu is reported in the literature to be less stable at high concentrations in unbuffered water than in buffered systems. Some method papers recommend mild buffering and freshly prepared aliquots when the assay readout is sensitive to copper state.
GHK in solution is more stable to light and heat than GHK-Cu but will scavenge available copper from any system that supplies it, which can be a design consideration in cell culture work with copper-containing media.

For both compounds, freeze-thaw cycling of reconstituted stocks should be minimized. Single-use aliquots prepared on reconstitution are the safer default.

Summary

GHK and GHK-Cu are the same tripeptide backbone in two different states. GHK is the free Gly-His-Lys tripeptide. GHK-Cu is the same molecule pre-complexed with a Cu(II) ion at the histidine-imidazole/N-terminal coordination site. The molecular weights differ by approximately 62 Da, the colors differ visibly, the CAS numbers differ, and the CoA expectations differ in the specific question of copper content.

The two are not interchangeable in research designs that depend on copper availability or on a defined 1:1 starting stoichiometry. The majority of the published regenerative and tissue-remodeling literature uses GHK-Cu. The Campbell 2012 lung-tissue transcriptomic work used the free tripeptide. Match the form to the reference paper, document the choice in the methods section, and confirm both identity and copper content on the CoA before the compound enters the experimental workflow.

Selected peer-reviewed sources

Pickart L. The human tripeptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition 2008; 19(8): 969-988. DOI: 10.1163/156856208784909435
Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences 2018; 19(7): 1987. DOI: 10.3390/ijms19071987
Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International 2015; 2015: 648108. DOI: 10.1155/2015/648108
Campbell JD, McDonough JE, Zeskind JE, Hackett TL, Pechkovsky DV, Brandsma CA, et al. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Medicine 2012; 4(8): 67. DOI: 10.1186/gm367
Hong Y, Downey T, Eu KW, Koh PK, Cheah PY. A ‘metastasis-prone’ signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics. Cosmetics (Hong et al., 2015 GHK-Cu transcriptomic profiling). DOI: 10.3390/cosmetics2020085
Zhou XM, Wang GL, Wang XB, Liu L, Zhang Q, Yin Y, et al. GHK peptide inhibits bleomycin-induced pulmonary fibrosis in mice by suppressing TGFβ1/Smad-mediated epithelial-to-mesenchymal transition. Frontiers in Pharmacology 2017; 8: 904. DOI: 10.3389/fphar.2017.00904
Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters 1988; 238(2): 343-346. DOI: 10.1016/0014-5793(88)80509-X
Pickart L, Vasquez-Soltero JM, Margolina A. The effect of the human peptide GHK on gene expression relevant to nervous system function and cognitive decline. Brain Sciences 2017; 7(2): 20. DOI: 10.3390/brainsci7020020
Pickart L, Margolina A. The biological effects of a tripeptide-copper complex GHK-Cu on the human body. Brazilian Archives of Biology and Technology 2012; 55(5): 689-696.
Pickart L, Vasquez-Soltero JM, Pickart FD, Majnarich J. GHK, the human skin remodeling peptide induces anti-cancer expression of numerous caspase, growth regulatory, and DNA repair genes. Journal of Analytical Oncology 2014; 3(2): 79-87. DOI: 10.6000/1927-7229.2014.03.02.4

Research Use Only — Disclaimer

All compounds discussed in this article are described for laboratory and research purposes only. They are intended exclusively for in vitro experimentation and use in animal studies under appropriate institutional oversight. They are not drugs, dietary supplements, cosmetics, or food additives. They are not for human consumption and not for any therapeutic, diagnostic, preventive, or palliative purpose.

Nothing in this article constitutes medical advice. No statement should be interpreted as a recommendation that any peptide compound is safe, effective, or appropriate for any use in humans.

Buyers must be at least 21 years of age and must agree to use products strictly for research purposes.